A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2004
12/28/2004	CA2331297C Hygromycin a derivatives
12/23/2004	WO2004110487A1 Treatment of t cell mediated diseases by inhibition of fgfr3
12/23/2004	WO2004110404A1 Combined doses of tiotropium and fluticasone
12/23/2004	WO2004110392A2 Compositions and methods for treating coronavirus infection and sars
12/23/2004	WO2004110390A2 Anti-cd74 immunoconjugates and methods
12/23/2004	WO2004110386A2 Molecular interaction sites of coronavirus rna and methods of modulating the same
12/23/2004	WO2004110384A2 Hiv-1 envelope glycoproteins having unusual disulfide structure
12/23/2004	WO2004110381A2 Pharmaceutical compositions comprising active vitamin d compounds
12/23/2004	WO2004110380A2 Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
12/23/2004	WO2004110379A2 A1 adenosine receptor antagonists
12/23/2004	WO2004110378A2 Treatment alzheimer's disease with r(-) 2-arylproponic acid nsaid alone or in combination with selective cox-2 inhibitor
12/23/2004	WO2004110376A2 Ccr-2 antagonists for treatment of neuropathic pain
12/23/2004	WO2004110375A2 Combination therapy for the treatment of diabetes
12/23/2004	WO2004110374A2 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
12/23/2004	WO2004110373A2 Therapeutic vaccine compositions for the treatment of type 1 diabetes
12/23/2004	WO2004110372A2 Room temperature storage of organs
12/23/2004	WO2004110371A2 Method for the treatment of malignancies
12/23/2004	WO2004110370A2 Etiologic agnet for sow infertility syndrome
12/23/2004	WO2004110369A2 Cell surface protein associated with human chronic lymphocytic leukemia
12/23/2004	WO2004110368A2 Combination therapy for the treatment of hypertension
12/23/2004	WO2004110367A2 Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
12/23/2004	WO2004110366A2 Sunscreen composition
12/23/2004	WO2004110364A2 Thiotungstate analogues and uses thereof
12/23/2004	WO2004110363A2 Method of inhibiting tumor growth with anti-tissue factor antibodies
12/23/2004	WO2004110362A2 Immunotherapeutics for biodefense
12/23/2004	WO2004110361A2 Anticancer compositions comprising methenamine
12/23/2004	WO2004110360A2 Proteoglycan degrading mutants for treatment of cns
12/23/2004	WO2004110359A2 Fusion proteins for the treatment of cns
12/23/2004	WO2004110356A2 Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
12/23/2004	WO2004110355A2 Compositions and methods including a recombinant human mab that promotes cns remyelination
12/23/2004	WO2004110354A2 Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
12/23/2004	WO2004110353A2 Novel immunomodulating peptide
12/23/2004	WO2004110352A2 Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
12/23/2004	WO2004110351A2 Heterocyclic compounds for treating hepatitis c virus
12/23/2004	WO2004110350A2 Compouds and uses thereof in modulating amyloid beta
12/23/2004	WO2004110349A2 Sars t cell epitopes and methods for identifying same
12/23/2004	WO2004110348A2 Saururus cernuus compounds that inhibit cellular responses to hypoxia
12/23/2004	WO2004110347A2 Compositions and methods for reducing scar tissue formation
12/23/2004	WO2004110345A2 Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
12/23/2004	WO2004110344A2 New azetidine compounds
12/23/2004	WO2004110343A2 2-amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]- 2- aminopurine using the same
12/23/2004	WO2004110342A2 Novel polymorph of gabapentin and its conversion to gabapentin form-ii
12/23/2004	WO2004110341A2 Antimicrobial and anticancer lipopeptides
12/23/2004	WO2004110340A2 Ctla-2 and uses thereof
12/23/2004	WO2004110339A2 Method for selective targeting of apoptotic cells and small molecule ligands used thereof
12/23/2004	WO2004110338A2 Methods of treating obesity and related disorders using tellurium and selenium compounds
12/23/2004	WO2004110337A2 Cell permeable conjugates of peptides for inhibition of protein kinases
12/23/2004	WO2004099150A3 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands
12/23/2004	WO2004098503A3 Drug releasing biodegradable fiber for delivery of therapeutics
12/23/2004	WO2004096145A3 Hemorrhoid treatment device
12/23/2004	WO2004091482A3 M3 muscarinic acetylcholine receptor antagonists
12/23/2004	WO2004087048A3 Benzamide modulators of metabotropic glutamate receptors
12/23/2004	WO2004082588A3 Dispersible formulation of an anti-inflammatory agent
12/23/2004	WO2004080416A3 Animal model simulating neurologic disease
12/23/2004	WO2004078128A3 Substituted pyridine derivatives useful in the treatment of cancer and other disorders
12/23/2004	WO2004071447A3 Substituted azole derivatives as therapeutic agents
12/23/2004	WO2004071429A3 Lung inflammation treatment
12/23/2004	WO2004064771A3 Geminally di-substituted nsaid derivatives as abeta 42 lowering agents
12/23/2004	WO2004056317A3 Compositions for the treatment and prevention of nephropathy
12/23/2004	WO2004054497A3 Use of a trpm8-activating substance for the treatment of tumours
12/23/2004	WO2004041213A3 Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
12/23/2004	WO2004032823A3 Treatment and rehydration composition which is used to limit the side effects of gastro-enteritis in adults
12/23/2004	WO2003106491A3 Cell penetrating peptides
12/23/2004	US20040260234 Apparatus and methods for repetitive microjet durg delivery priority statement
12/23/2004	US20040260152 Speculum assembly
12/23/2004	US20040259931 An urea derivative containing amide, amine or substitued amine groups and pyrrolidine ring(s), useful for treating obesity, anxiety or depression
12/23/2004	US20040259929 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
12/23/2004	US20040259925 Pharmaceutical compositions and methds for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
12/23/2004	US20040259921 EP4 receptor selective agonists in the treatment of osteoporosis
12/23/2004	US20040259919 for the treatment of diabetes, hyperglycemia, hypoglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, eating disorders, and nervous system disorders
12/23/2004	US20040259906 Methods for controlling the proliferation of cells
12/23/2004	US20040259896 N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions
12/23/2004	US20040259886 Compositions and methods for treating osteoporosis and lowering cholesterol
12/23/2004	US20040259878 Noninvasive monitoring tumor tissue concentration of an anticarcinogenic agent in real time using magnetic resonance spectroscopy of these nontoxic compounds to determine the sensitivity of or resistance of a tumor to methotrexate; predicting the efficacy of methotrexate therapy and planning strategy
12/23/2004	US20040259870 Antidiabetic agents; obesity; controlling appetite
12/23/2004	US20040259862 Method of treating functional bowel disorders
12/23/2004	US20040259851 Methods of administering estrogens and progestins
12/23/2004	US20040259844 Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
12/23/2004	US20040259839 Foods, printing dyes, oil well drilling fluids, ceramic glaze, drugs
12/23/2004	US20040259832 Synergistic mixture of thymidine kinase inhibitor and viricides
12/23/2004	US20040258777 Aqueous topical solutions stimulate endothelial growth factors and microcirculation; solvent extraction with volatile non-aqueous solvents; obestity; reduction of cellulite and localized dermal adipose deposits
12/23/2004	US20040258739 Plaster for the treatment of dysfunctions and disorders of nails
12/23/2004	US20040258724 Gilsonite oil and drug for topical or transdermal drug delivery to skin or nails; penetration ehancement
12/23/2004	US20040258699 Treating an animal infected with Bacillus anthracis by administering an antibody or antibody fragment having binding affinity to the protective antigen of Bacillus anthracis and the ability to block binding of the protective antigen to cell receptors, edema factor and lethal factor; vaccines
12/23/2004	US20040258698 Delivery of immune response modifier compounds
12/23/2004	US20040258687 Use of GCC ligands
12/23/2004	US20040258671 Delivering antiinflammatory cytokines to nervous system using gene therapy techniques
12/23/2004	US20040258626 Combination of medicament and lactose particles; accurate, uniform, consistent dispersion for multidose dry powder inhaler
12/23/2004	US20040258621 Method of treating snoring and other obstructive breathing disorders
12/23/2004	US20040258616 Compositions and methods for treating cancer using IGSF9 and LIV-1
12/23/2004	CA2563361A1 Cell permeable conjugates of peptides for inhibition of protein kinases
12/23/2004	CA2530634A1 Methods of treating obesity and related disorders using tellurium and selenium compounds
12/23/2004	CA2529496A1 Anti-cd74 immunoconjugates and methods
12/23/2004	CA2529486A1 Method for selective targeting of apoptotic cells and small molecule ligands used thereof
12/23/2004	CA2529127A1 Combined doses of tiotropium and fluticasone
12/23/2004	CA2529125A1 Antimicrobial and anticancer lipopeptides
12/23/2004	CA2528552A1 Pharmaceutical compositions comprising active vitamin d compounds
12/23/2004	CA2528547A1 Saururus cernuus compounds that inhibit cellular responses to hypoxia
12/23/2004	CA2528378A1 Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
12/23/2004	CA2528367A1 A1 adenosine receptor antagonists

1 ... 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 ... 295